Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), the immunotherapies specialist, said it is presenting two posters at an industry conference in Germany on Friday that will provide fresh insights about its monoclonal antibodies technology.
The first, entitled ‘Unlocking the unique potential of AvidiMab in fighting cancer’, will outline new data on the company’s AvidiMab and GlyMab platforms.
The second, ‘GlyMabs, glycome-targeting monoclonal antibodies for cancer therapy’, will see Scancell highlight the enhanced targeting and binding specifics for candidates created from the GlyMab technology.
The updates will be provided to delegates at the EuroMAbNet 12th Annual Meeting in Hamburg.
Scancell chief executive, professor Lindy Durrant, said: “Our proprietary antibody platforms leverage our skills and knowledge in immunology and we are excited about the future potential they give in creating truly differentiated product candidates for the treatment of certain types of cancer.
“The preclinical data being presented at EuroMAbNet illustrates the versatility and specificity of our platforms in generating novel antibody drug candidates using our GlyMab technology and enhancing their anti-cancer potential with AvidiMab.”